Sunday, July 27, 2008

Foundation Funds Follow-up Care in Revolutionary Cancer Vaccine Study

Onyx and Breezy Foundation Funds Follow-up Care in Revolutionary Cancer Vaccine Study

The Onyx & Breezy Foundation recently funded after-care for dogs engaged in a revolutionary research study to develop a cancer vaccine that may be given to both humans and animals when successful. The study is being conducted at The Matthew J. Ryan Veterinary Hospital, a small animal teaching hospital affiliated with the University of Pennsylvania in Philadelphia.

Tuxedo Park, NY and Philadelphia, PA  -  March 14 -- The Onyx & Breezy Foundation has announced a gift to The University of Pennsylvania School of Veterinary Medicine. The gift will cover the expense of follow-up care for 12 dogs that are currently enrolled in the School's cancer vaccine study.

"Thanks to this generous gift, more participants in our lymphoma cancer vaccine clinical trial will be able to return for follow-up care," said Dr. Karin Sorenmo, chief of oncology at the Matthew J. Ryan Veterinary Hospital. "This means that we can capture all the data that is needed for the study while pet owners are helped financially."

Prior gifts to The Matthew J. Ryan Veterinary Hospital from the Foundation have been a respirator for their ICU department and a mast cell tumor research study.

Dr. Sorenmo treated Breezy, who had mast cell tumors. "Thanks to Dr. Sorenmo, Breezy lived another 2 years, of quality life, after other vets gave her only 6 weeks to live," said Wanda Shefts. "We are glad that this project will help owners of dogs in remission from lymphoma and help advance Dr. Sorenmo's work on the cancer vaccine.

Dr. Sorenmo stated that she was encouraged by the results and she is hoping that this is just the beginning of more trials that can benefit dogs and ultimately help people. Thanks to this study, a number of the participating dogs are now cancer free. The researchers now estimate that they are within two years of testing the vaccine on humans. Without the dogs, they would be more than a decade away.

"We have a tremendous amount of respect for the work they do at the Hospital and we are glad to be able to fund another project for them", said Mark Shefts.

For more information about Penn Vet, please visit
www.vet.upenn.edu; for more information about The Onyx and Breezy Foundation, please visit www.onyxandbreezy.org.

The Onyx and Breezy Foundation Background

The Foundation was created in 2004 and named after the trustees Mark & Wanda Shefts' two Labrador Retrievers. The Foundation lends financial support to organizations that benefit the welfare of animals.

The University Of Pennsylvania School Of Veterinary Medicine Background

Penn's School of Veterinary Medicine is one of the world's premier veterinary schools. Founded in 1884, the School was built on the concept of Many Species, One MedicineTM. The birthplace of veterinary specialties, the School serves a distinctly diverse array of animal patients, from pets to horses to farm animals.

Press Contact: Barbara Kauffman
Company Name: The Onyx & Breezy Foundation
Phone: 201-782-7400
Website:
www.onyxandbreezy.org

Wednesday, July 09, 2008

Baxter Heparin Information on Additional Heparin Recall

LegalView Expands Baxter Heparin Information Portal to Include Information on an Additional Heparin Recall

LegalView updated its Baxter Heparin information portal to add information on the most recent recall of the blood-thinning drug. Heparin, which is used to control blood during surgical procedures, was recently discovered to have a Heparin-like contaminant that sickened many and caused at least 19 deaths.

Denver, CO  -  March 31, 2008 -- The Baxter Heparin practice area on LegalView's site, the source for everything legal on the Web, was recently expanded to explain details of an additional Heparin recall . Heparin has been linked to hundreds of allergic reactions among patients as well as having been connected with 19 deaths. B. Braun Medical Inc. issued the most recent recall of Heparin, which was supplied from Scientific Protein Laboratories - the same company that supplied Baxter Healthcare Corporation with the contaminated Baxter Heparin. According to the U.S. Food and Drug Administration (FDA) and B. Braun Medical Inc., no one was reportedly sickened off of the Heparin from B. Braun Medical but it did have a "heparin-like contaminant," which was enough for the company to recall the drug.

Heparin is blood-thinner injected into patients who are undergoing surgical procedures such as heart disease or kidney dialysis. It is a drug that has been imported to the United States since the 1930s and is derived from pig intestines. Many surgeons find that Heparin is an extremely important drug because it prevents blood clots from forming during surgery, which can result in death among patients. However, earlier this year, a rash of individuals who had been given Heparin during a surgical procedure had allergic reactions. Individuals who have been affected by the contaminated Heparin should consider contacting a Heparin lawyer to learn about developing a Heparin class action lawsuit for which compensation may be derived from manufacturers if the tainted drug.

The Baxter Heparin that was initially recalled had been tainted with a chemical known as over-sulfated chondroitin sulfate. Through an FDA investigation, it was discovered that a Chinese company that produces the drug was responsible for the tainted Heparin. Although an investigation continues to be ongoing as to whether the chemical was intentionally or accidentally introduced into a batch of the Heparin. According to news reports, using the over-sulfated chondroitin sulfate allows for a reduction in the production of production for Heparin.

For information on additionally recalled prescription drugs or to report an adverse reaction to a prescribed drug, visit LegalView's many unsafe drugs information portals. Here, readers will find information on recently recalled drugs as well as prescription drugs under investigation such as Chantix, Avandia and Trasylol Aprotinin.

Chantix is a smoking cessation drug from Pfizer that was first introduced to the market, with FDA approval, in mid-2006. However, in late-2007 the FDA began an investigation into nearly 400 reports of suicidal tendencies and behaviors among patients. Additionally, nearly 37 suicides have been associated with the Chantix side effects, which include psychotic episodes, depression, suicidal thoughts and erratic behavior.

Avandia is a prescription drug used to treat diabetes 2 among patients; however, the drug has been linked to several serious side effects including an increased risk of heart disease and a higher chance of early onset osteoporosis. Individuals who are taking Avandia are advised to locate an experienced pharmaceutical law firm to receive consultation on an Avandia lawsuit.

Trasylol, also known as its generic version Aprotinin, is similar to Heparin in that it is used during surgical procedures to control blood loss. A study was released in 2006 from the New England Journal of Medicine, which found that the use of Trasylol Aprotinin increased the chances of a patient developing heart disease, kidney disease, stroke and death. Patients who received or may have received Trasylol or it's generic version should use LegalView's information portal to find an Trasylol attorney.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website:
http://baxter-heparin.legalview.com

Tuesday, July 08, 2008

Eating Between The Lines

A Health Diary and Food Journal for the Rest of Us

For women who would like to keep a food diary, exercise log and health journal in two minutes a day or less. The Bio-Diary for Women by FitMinder is an easy-to-use alternative to food and exercise journals that require tedious daily entries. Its unique format offers and useful and beautiful tool to record and analyze health information.

Sacramento, CA, June 25, 2008 -- Keeping a food diary or health journal is highly recommended these days as a way to manage diet and health. But many people are put off by the thought of recording every bite they eat. They are too busy living their lives to spend the day recording it. Now there's an alternative for people who want to track diet, exercise, and health issues, without the tedious detail.

Most food journals and exercise logs are designed for people who are committed to detailed daily tracking of their progress. But what about people who can't commit to that level, but still want the usefulness of a food diary, exercise log, and health journal -- for things like illnesses, medications, sleep problems, allergies, stress, energy level and other health issues? And what if the most time they could commit was a couple of minutes, once a day?

Marie Karner, a Sacramento business owner, has been keeping a health journal for six years, and has designed a simple and effective tool for women who only have time for the big picture. For those whose life speedometer runs in weeks or months -- not hours or days, the Bio-Diary's "quick-scan" format helps manage health info and keep goals in sight.

The Bio-Diary for WomenT uses a simple monthly log book format with columns, and tracks one month at a time, using eight different pages. Two minutes is about all it takes to jot down one day's worth of meals, exercise, health symptoms and other info. The format is flexible and can be customized to suit different needs. Because it provides a snapshot view of months at a glance, it is particularly useful in identifying cause-and-effect relationships, and analyzing patterns and trends. Each month features a diary page for moments when a minute or two of writing is not only therapeutic, but useful as well.

The Bio-Diary for WomenT is available online at Amazon and also at FitMinder Publishing's website at fitminder.com.

Contact Information
FitMinder Publishing
Marie Karner
916-635-0511
mariek@fitminder.com
www.fitminder.com

Sunday, July 06, 2008

Asbestos Contaminated Housing Project Crews Hid Asbestos Leak

LegalView Releases News on Asbestos Contaminated Housing Project Where Crews Hid Asbestos Leak with Dirt

LegalView reported on its mesothelioma blog about an asbestos contamination that occurred in Miami during the construction of an affordable housing project. The project, now likely to cost five times the original estimate, was contaminated after crews clearing the area hid an asbestos leak with piles of dirt.

Denver, CO  -  April 12 -- LegalView.com updated its mesothelioma blog with reports of an asbestos contamination that was concealed with piles of dirt by construction crews who were clearing the area for an affordable housing project. The contamination not only increased the risk of exposure to asbestos and thus development of mesothelioma for individuals in the area, but increased the cost of the affordable housing project by five times the originally estimated amount. Individuals living in the area may have been exposed to asbestos fibers and are urged to contact a medical professional as soon as possible. Additionally, Americans who may have been exposed to asbestos should also contact an experienced mesothelioma law firm.

Asbestos is derived vermiculite, a mineral that was heavily mined in the 20th Century. Asbestos was prized for its ability to insulate buildings with a decreased risk of catching fire. It was used for all types of constructions including schools, offices, homes and apartment buildings. However, after discovering that asbestos exposure caused a deadly lung disease among exposed individuals, mining stopped and the Environmental Protection Agency (EPA) was charged with the task of cleaning up any asbestos. Mesothelioma cancer, which is an untreatable form of lung cancer, is often the outcome for individuals who were previously exposed to asbestos. Those who feel they are at risk for this illness should locate an attorney to explore the possibility of a mesothelioma lawsuit.

The area known as North Miami's Pioneer Gardens was expected to house 136 units for low-income individuals. However, when a contractor began digging, it was discovered that workers who had previously cleared the site had inadvertently caused an asbestos leak when underground pipes containing the contaminant were broken. The workers allegedly covered the leak with piles of dirt and it was left until just recently when digging began. It can take years to develop the cancer and even then a mesothelioma diagnosis is often overlooked, causing the cancer to spread among its victim. To learn about the potential for monetary compensation, individuals are advised to contact an experienced mesothelioma lawyer for an attorney consultation on their individual case.

Other issues that are covered on LegalView's Web site, which have largely negatively impacted thousands of Americans recently, include several prescription drugs - Chantix, Singulair, as well as Vytorin and Zetia. Chantix is a smoking cessation drug that is prescribed to millions of Americans struggling to quit their tobacco addiction. In late 2007, the U.S. Food and Drug Administration (FDA) began receiving reports from patients taking Chantix that the drug was linked with instances of depression, erratic behavior and suicidal tendencies and thoughts. Overall, nearly 400 individuals reported this behavior and the drug was also allegedly linked to 37 suicides among patients. The FDA quickly began investigating the drug and are currently studying the Chantix side effects to determine the drug's dangers.

Similar to the dangerous side effects that have been associated with Chantix, are those that have been linked to Singulair, also a prescription drug, which is given to patients who suffer from severe asthma and allergy symptoms. However, in March 2008, reports began to surface about Singulair's potentially dangerous side effects, which may include mood and behavior changes including suicidal behavior among adults and children. The FDA is currently investigating the Singulair risks that may exist with taking this drug.

Vytorin and Zetia are similar in that both are prescription drugs used to lower cholesterol and prevent heart disease among patients. Often Vytorin and Zetia are used in combination of each other and both are manufactured from Merck/Shering-Plough. Recently, the company made headlines because of an extensive study that was completed in 2006 on the two drugs, which detailed the benefits, or lack thereof, of the medications. However, the Zetia and Vytorin manufacturer allegedly delayed the release of the study to the public because findings that Vytorin and Zetia were not as effective as cheaper alternatives. This information has prompted many patients to consider a Vytorin lawsuit.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website:
http://mesothelioma.legalview.com

Wednesday, July 02, 2008

Program to Protect Consumers Against Fraud

MoneyGram Announces Program to Protect Consumers Against Fraud

MINNEAPOLIS-- July 02, 2008 --MoneyGram International is adding to its existing efforts to protect consumers from fraud-induced money transfers in response to concerns from state Attorneys General. Through an agreement of voluntary compliance, MoneyGram is taking steps to enhance consumer protections and further address the problem of wire transfer fraud. The company and 44 states plus the District of Columbia are cooperating on a five-year plan to raise public awareness of the dangers of fraud through a variety of tactics including enhanced consumer education, more prominent fraud warnings for money transfer customers and enhanced training for agents.

Besides enhancing its own education efforts, MoneyGram will contribute $1.1 million to the AARP Foundation for Consumer Education to fund a fraud awareness program aimed at the elderly, who are often targets for fraud. This program is expected to get underway in the next three to six months.

"We are very pleased to help launch this program," said Tony Ryan, Executive Vice President and Chief Operating Officer of MoneyGram International. "We are committed to helping to stop fraud and protect consumers, and we know that this is an issue that none of us can tackle alone."

"AARP Foundation's fight against consumer fraud advances AARP's goal of ensuring the economic security of people 50 and over," said AARP Foundation President Robin Talbert. "Preventing consumer fraud and abuse are critical components of financial security. AARP, the AARP Foundation and hundreds of community volunteers have been fighting fraud directed at older consumers for more than 10 years. We are very proud of our outreach and education."

MoneyGram will also pay $150,000 to the Attorneys General Executive Committee to cover costs.

MoneyGram International, Inc. is a leading global payment services company. The company's major product and services include global money transfers, money orders and payment processing solutions for financial institutions and retail customers. MoneyGram has 152,000 global money transfer locations in 180 countries and territories. For more information, visit the company's website at www.moneygram.com.

Contacts

MoneyGram International
Michael Fox, 203-682-8218
mfox@icrinc.com

Tuesday, July 01, 2008

Sterilisation and Disinfectant Markets in Europe

Sterilisation and Disinfectant Markets in Europe Enjoy Mixed Fortunes

LONDON-- July 01, 2008 --The sterilisation and disinfectant market in Europe has been witnessing slow growth as hospitals try to tackle alarmingly high infection rates resulting from inadequately decontaminated patient care equipment. However, the market is mature and saturated, offering little scope for technological innovation, and the complete lack of product differentiation is hampering competition. While the disinfection market has shown potential for expansion, the sterilisation market remains largely static.

New analysis from Frost & Sullivan (
http://www.medicaldevices.frost.com), European Sterilisation and Disinfection Equipment Market, finds that the market earned revenues of over USD269.7 million in 2007 and estimates this to reach USD352.0 million in 2014.

"Though the sterilisation and disinfection equipment market is not characterised by a strong level of technological development, certain mutations are contributing to the overall positive growth," says Frost & Sullivan Research Analyst Kieu A. Vuong. "For instance, slack growth in the low-temperature gas steriliser segments is compensated by positive trends impacting the disinfector equipment sector."

The spurt in the number of surgical procedures utilising minimally invasive instruments such as endoscopes is also driving the need for sophisticated systems for proper disinfection and maintenance of such equipment. This demand for more efficient disinfecting methods is fuelling the growth of the automatic endoscope reprocessor (AER) segment. The washers and AER disinfection markets are exhibiting continuous growth due to advancements in surgical instrumentation and liquid chemical disinfectants as well.

However, emerging trends indicate increasing consolidation and centralisation of hospitals in Europe, drastically reducing the number of hospitals and the number of potential customers. End-user consolidation is a challenge for this market, as purchasing power is augmented.

"High prices along with slow rate of product replacement will force manufacturers to identify different revenue streams in order to maintain and increase their profit margins," notes Vuong. "Despite several attempts at creating a unified platform, insecurities concerning the standardisation and regulation of products continue."

Nonetheless, participants can accrue revenues by providing integrated service packages and proper nurturing of customer relationships, since virtually all hospitals are already equipped with infection control equipment. To achieve the high standards required for service packages, many companies have entered into partnerships to reduce costs and enhance their offering.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European sterilisation and disinfection equipment market, then send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Sterilisation and Disinfection Equipment Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: cardiovascular, wound care, surgical, orthopaedic and others. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team MembershipT empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit
http://www.frost.com.

European Sterilisation and Disinfection Equipment Market

M236

Contacts

Frost & Sullivan
Corporate Communications - Europe & Africa
Patrick Cairns, +27 18 468 2315
patrick.cairns@frost.com
or
Corporate Communications - North America
Stacie Kopecki, 210-247-2450
fax: 210-348-1003
stacie.kopecki@frost.com
or
Corporate Communications - Asia Pacific
Jasminder Kaur, 65-6890-0937
fax: 65-6890-0988
jkaur@frost.com
or
Corporate Communications - South Asia
Remi Chatterjee, +91-44-4001 3419
fax: +91-22-2832 4713
remi.chaterjee@frost.com
or
Corporate Communications - Middle East
Nimisha Iyer, +91 22 4001 3404
fax: +91 22 2832 4713
niyer@frost.com
or
Corporate Communications - China
Amelia Wong, +86 21 5407 5783, ext. 8669
cell: +86 13621724823
amelia.wong@frost.com
or
Corporate Communications - Latin America
José María Jantus, + 54-11-4777-9951
fax: + 54-11-4777-0071
jose.jantus@frost.com
http://www.frost.com